Statistical power and validity of Ebola vaccine trials in Sierra Leone: A simulation study of trial design and analysis

The Lancet Infectious Diseases

Volumn 15, Issue 6, 2015, Pages 703-710

  Bellan, Steven E ^a   Pulliam, Juliet R C ^b   Pearson, Carl A B ^b   Champredon, David ^c   Fox, Spencer J ^a   Skrip, Laura ^e   Galvani, Alison P ^e   Gambhir, Manoj ^f,g,i   Lopman, Ben A ^h,j   Porco, Travis C ^k,l   Meyers, Lauren Ancel ^a,m   Dushoff, Jonathan ^d  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e YALE UNIVERSITY   (United States)

^f MONASH UNIVERSITY   (Australia)

^g NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^h NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

ⁱ Ihrc Inc   (United States)

^j EMORY UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m SANTA FE INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

ARTICLE; BOOTSTRAPPING; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; POISSON DISTRIBUTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIERRA LEONE; SIMULATION; STATISTICAL PARAMETERS; STOCHASTIC MODEL; STUDY DESIGN; VACCINATION; VALIDITY; BIOSTATISTICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MEDICAL RESEARCH; PROCEDURES;

BIOMEDICAL RESEARCH; BIOSTATISTICS; EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIERRA LEONE;

EID: 84929518411     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70139-8     Document Type: Article

References (22)

1. Mohammadi D Ebola vaccine trials back on track. Lancet 2015, 385:214-215.
2. STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Centers for Disease Control and Prevention, (accessed March 20, 2015). https://clinicaltrials.gov/ct2/show/NCT02378753.
3. Enserink M High hopes for Guinean vaccine trial. Science 2015, 347:219-220.
4. Van der Graaf R, van Delden JJM Equipoise should be amended, not abandoned. Clin Trials 2011, 8:408-416.
5. Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014, 384:1423-1424.
6. Brown CA, Lilford RJ The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006, 6:54.
7. Mdege ND, Man MS, Taylor C, Torgerson DJ Systematic review of stepped wedge cluster randomized trials shows that design is particularly used to evaluate interventions during routine implementation. J Clin Epidemiol 2011, 64:936-948.
8. Cornfield J Randomization by group: a formal analysis. Am J Epidemiol 1978, 108:100-102.
9. Kerry SM, Bland JM Sample size in cluster randomisation. BMJ 1998, 316:549.
10. Hayes RJ, Bennett S Simple sample size calculation for cluster-randomized trials. Int J Epidemiol 1999, 28:319-326.
11. Sub-national time series data on Ebola cases and deaths in Guinea, Liberia, Sierra Leone, Nigeria, Senegal and Mali since March 2014 Humanitarian Data Exchange, (accessed Feb 20, 2015). https://data.hdx.rwlabs.org/dataset/rowca-ebola-cases.
12. Pearson C, Porco TC Web-based Ebola forecasting tool (accessed Feb 10, 2015). http://ebola.ici3d.org/ebola_forecast.
13. Lopman B Can effectivness be accurately estimated using a phased introduction of an Ebola vaccine? In: Modeling the Spread and Control of Ebola in West Africa. Atlanta (accessed Feb 10, 2015). http://bioinformatics.gatech.edu/ebola-modeling-workshop-program.
14. Cohen J, Kupferschmidt K Ebola vaccine trials raise ethical issues. Science 2014, 346:289-290.
15. Kilmarx PH, Clarke KR, Dietz PM, Hamel MJ, Husain F, McFadden JD Ebola virus disease in health care workers-Sierra Leone, 2014. Morb Mortal Wkly Rep 2014, 63:1168-1171.
16. Geisbert TW, Feldmann H Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections. J Infect Dis 2011, 204:S1075-S1081.
17. Rampling T, Ewer K, Bowyer G, et al. A monovalent chimpanzee adenovirus ebola vaccine-preliminary report. N Engl J Med 2015, published online Jan 28. 10.1056/NEJMoa1411627.
18. Faye O, Boëlle P, Heleze E, et al. Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study. Lancet Infect Dis 2015, 15:320-326.
19. Bellan SE, Pulliam JRC, Dushoff J, Meyers LA Ebola virus vaccine trials: the ethical mandate for a therapeutic safety net. BMJ 2014, 349:g7518.
20. Wolbers M, Kleinschmidt I, Simmons CP, Donnelly CA Considerations in the design of clinical trials to test novel entomological approaches to dengue control. PLoS Negl Trop Dis 2012, 6:e1937.
21. Van der Tweel I, van der Graaf R Issues in the use of stepped wedge cluster and alternative designs in the case of pandemics. Am J Bioeth 2013, 13:23-24.
22. Davies MM, Van Der Laan MJ A new approach to variance estimation for time-ordered dependent data. U.C. Berkeley Division of Biostatistics Working Paper Series. Working Paper 322 (accessed Feb 15, 2015). http://biostats.bepress.com/ucbbiostat/paper322.